Adial Pharmaceuticals (ADIL) Other Non-Current Assets (2017 - 2023)
Adial Pharmaceuticals (ADIL) posted Other Non-Current Assets of $428700.0 for Q1 2023, little changed sequentially from $428700.0 in Q4 2022, and up 83.54% YoY from $233570.0 in Q1 2022.
Adial Pharmaceuticals (ADIL) Other Non-Current Assets (2017 - 2023) Analysis & Trends
Adial Pharmaceuticals has reported Other Non-Current Assets for 7 years, with the latest figure at $428700.0 in Q1 2023.
- Quarterly Other Non-Current Assets rose 83.54% year-over-year to $428700.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $428700.0 (up 83.54% YoY) and the FY2022 annual result came in at $428700.0, up 74.12% from the prior year.
- Other Non-Current Assets was little changed at $428700.0 in Q1 2023 per ADIL's latest filing, from $428700.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $428700.0 in Q4 2022 and troughed at $5747.0 in Q3 2020.
- A 5-year average of $133419.1 and a median of $6522.5 in 2019 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2020 and 2023: Other Non-Current Assets decreased 8.94% in 2020, then jumped 83.54% in 2023.
- Over 5 years, Other Non-Current Assets stood at $6170.0 in 2019, then decreased by 6.86% to $5747.0 in 2020, then jumped by 4184.13% to $246209.0 in 2021, then soared by 74.12% to $428700.0 in 2022, then changed by 0.0% to $428700.0 in 2023.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $428700.0, $428700.0, and $220660.0 for Q1 2023, Q4 2022, and Q2 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 428,700.00 |
| Dec 31, 2022 | 428,700.00 |
| Jun 30, 2022 | 220,660.00 |
| Mar 31, 2022 | 233,570.00 |
| Dec 31, 2021 | 246,209.00 |
| Sep 30, 2020 | 5,747.00 |
| Jun 30, 2020 | 5,888.00 |
| Mar 31, 2020 | 6,029.00 |
| Dec 31, 2019 | 6,170.00 |
| Sep 30, 2019 | 6,311.00 |
| Jun 30, 2019 | 6,452.00 |
| Mar 31, 2019 | 6,593.00 |
| Dec 31, 2018 | 6,735.00 |
| Sep 30, 2018 | 6,875.00 |
| Jun 30, 2018 | 7,017.00 |
| Dec 31, 2017 | 7,298.00 |